Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunologic Activity of APN401 in Advanced Solid Tumors
NCT03087591Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APN401 in pancreatic cancer (PC), colorectal cancer (CRC) and solid tumor, sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Adverse Events Common Terminology Criteria for Adverse Events Version 4.0 up to 1 year. Started Apr 2017; status: completed.
02
Drugs
APN401
03
Conditions
pancreatic cancer (PC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT03087591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087591.